Olavex 5/Olavex 10

Olanzapine

Treatment of schizophrenia & moderate to severe manic episode. Prevention of recurrence in patients w/ bipolar disorder.

Adult Schizophrenia Starting dose: 10 mg daily. Manic episodes Initially 15 mg daily as monotherapy or 10 mg daily in combination therapy. Preventing recurrence in bipolar disorder Initially 10 mg daily. Elderly ≥65 yr Initially 5 mg/day.

May be taken with or without food.

Hypersensitivity. Known risk of narrow-angle glaucoma.

Dementia-related psychosis &/or behavioral disturbances. Risk of cerebrovascular accident. Parkinson's disease. Discontinue if neuroleptic malignant syndrome occurs. Hyperglycemia. May exacerbate preexisting diabetes w/ ketoacidosis or coma. Prostatic hypertrophy or paralytic ileus. Patients w/ elevated hepatic transaminases, renal or hepatic impairment or hepatitis (discontinue). Patients w/ low leukocyte/neutrophil count, agents known to cause neutropenia, history of or existing drug-induced bone marrow depression, hypereosinophilic conditions w/ myeloproliferative disease. History of seizures or factors which may lower seizure threshold. Discontinue or reduce dose if tardive dyskinesia occurs. Co-administration w/ drugs known to increase QTC interval especially in elderly, patients w/ congenital long QT syndrome, CHF, cardiac hypertrophy, hypokalemia or hypomagnesemia. Venous thromboembolism. Concomitant use w/ other CNS drugs or alcohol. Phenylketonuria. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Childn. Elderly ≥65 yr.

Eosinophilia, leukopenia, neutropenia, thrombocytopenia; hypersensitivity; wt gain, elevated cholesterol, glucose & triglyceride, glucosuria, increased appetite, exacerbation of preexisting diabetes, hypothermia; somnolence, dizziness, akathisia, parkinsonism, dyskinesia, seizures, dystonia, tardive dyskinesia, amnesia, dysarthria, neuroleptic malignant syndrome; bradycardia, QTc prolongation, ventricular tachycardia/fibrillation, sudden death, orthostatic hypotension, thromboembolism; epistaxis; mild transient anticholinergic effects including constipation, dry mouth, abdominal distension, pancreatitis; transient, asymptomatic elevations of hepatic transaminases (ALT, AST), hepatitis; rash, photosensitivity reaction, alopecia; arthralgia, rhabdomyolysis; urinary incontinence, retention & hesitation; erectile dysfunction, decreased libido, amenorrhea, breast enlargement, galactorrhea, gynecomastia, priapism; asthenia, fatigue, edema, pyrexia; elevated plasma prolactin levels, increased alkaline phosphatase, high creatinine phosphokinase & γ-glutamyltransferase & mic acid.

Decreased conc w/ smoking & carbamazepine. Increased conc w/ fluvoxamine. Decreased bioavailability w/ activated charcoal. May antagonize effects of direct & indirect dopamine agonists. Other drugs causing QT prolongation or metabolized by CYP1A2.

Antipsychotics

N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics

Rx